ClinicalTrials.gg
RecruitingNCT05950659WIREDUPUpdated Jul 14, 2026

WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention

An interventional study of Orpyx Sensory Insole System in Diabetes, Peripheral Neuropathy and Diabetic Foot, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Primary conditionDiabetic FootRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Foot
Why
  1. The study's listed conditions name Diabetic Foot, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Planned enrollment
13th of 322
400 · median 60
Started
2026
with 13 others
No phase
186 of 381
38 open now
Primary completion
2029-05
later than 80 of 83 live
Registered
296th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 13th largest by planned enrollment of the 322 interventional ones that give a count, is one of 14 that started in 2026, is one of 186 with no phase, reaches primary completion later than 80 of the 83 other live ones, and was the 296th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

The primary aim of this study is to demonstrate the impact of the Orpyx® Sensory Insoles (Orpyx Medical Technologies Inc., Calgary AB, Canada) ("Orpyx" or "the Company") as an adjunct to the standard of care (SOC), as compared to SOC alone, on reducing plantar ulceration incidence in individuals who are at risk for developing diabetic foot complications.

The secondary aims of this study are to evaluate participant quality of life, participant engagement, and economic impact, including cost-effectiveness and cost-utility. The study will also use the unique data set collected (plantar pressure, temperature, step count, movement and adherence feedback) to identify foot-loading histories that either lead to or prevent the development of ulceration in the diabetic foot.

03

Conditions studied

  • Diabetes
  • Peripheral Neuropathy
  • Diabetic Foot
  • Diabetic Foot Ulcer

Browse trials for

Keywords

  • Remote Patient Monitoring
  • Sensor-based Monitoring
  • Sensory Insoles
04

In context

Diabetic Foot Reclassified

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

This study's planned enrollment of 400 is above the median of 60 across 849 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.

Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.

Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed Type 1 or 2 diabetes
  • Clinically diagnosed neuropathy via Neuropathy Monofilament Test (Appendix A)
  • Qualification as a "high-risk participant," meaning a recent history (\<12 months) of a healed diabetic neuropathic ulceration on the weight-bearing surface of one or both feet (this includes the plantar distal toe surface)
  • Complete healing of any previous foot ulcers, as defined by complete re-epithelialization of that ulcer which is confirmed by two medical exams that occur at least two weeks apart (screening visit and baseline study visit)
  • Ability to walk independently (without use of wheelchair) for 30 steps. Use of a walker or cane is acceptable as long as the participant can walk for at least 30 steps.
  • Aged >18 years
  • ABI > 0.6 or TBI > 0.4 or palpable pulses or evidence of healing in the last 2 months. If ABI \< 0.4, the patient's vascular lab studies (ABI, TBI, pulse volume recordings) will be reviewed by the study PI and a co-I vascular surgeon at USC.
  • Subject is willing and able to maintain the required offloading (as applicable for the location of the healed ulcer)
  • Subject is willing and able to wear the Orpyx Sensory Insoles during ambulatory activity and at home during waking hours, and for a minimum of 5 hours per day
  • Amputations, if present, are compatible with the use of insoles at physician discretion (e.g. Transmetatarsal Amputation (TMA) are acceptable)

Exclusion criteria

Exclusion Criteria:

  • Active ulcer or presence of other open chronic wound (on foot or leg), regardless of etiology (e.g., vasculitis, neoplasms, or hematological disorders)
  • Dementia
  • Psychiatric illness or social situations that would limit compliance with the study
  • Significant cardiopulmonary, severe imbalance, or other systemic disease limiting the participant's ability to walk at least 30 steps or to stand for an amount of time equal to or greater than five (5) minutes (self-reported)
  • Current participation in another clinical investigation of a similar medical device designed to offload or prevent diabetic foot ulcer formation; or participation in such a study within 30 days prior to study enrollment, per physician discretion
  • Current enrollment in any other remote patient pedal monitoring (RPPM) program
  • Osteomyelitis or gangrene of the lower extremity
  • Uncorrected plantar Charcot neuroarthropathy
  • Bunion which would predispose ulcer formation (clinician discretion)
  • Extreme equinus
  • At the start of V1, and prior to randomization, the subject no longer meets the entrance criteria (inclusion and exclusion)
  • Above ankle amputation
  • Amputations not compatible with the insole, per physician discretion
  • Foot deformities or amputations that require surgical intervention as the next step in standard of care, and that the study footwear and device would not adequately address (to be adjudicated by an outside review panel).
  • Brannock-measured foot size > Men's 14 (Women's 12)
  • Physician discretion
06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Intervention

    Device: Orpyx Sensory Insole System

  • No intervention
    Control

Interventions

  • DeviceOrpyx Sensory Insole System

    The Orpyx Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading

07

What researchers measure

Primary outcomes

  1. Plantar ulcer recurrence

    Time frame: Baseline to End of Study (12 months)

Secondary outcomes

  1. Severity of Ulcer Recurrence

    Severity of ulcer recurrence will be quantified using the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system.

    Time frame: From Baseline to End of Study Visit (12 months)

  2. Participant quality of life

    Health-related quality of life will be evaluated based on patient responses on the EuroQol- 5 Dimension (EQ-5D), Patient Interpretation of Neuropathy (PIN), and Modified Diabetic Foot-Care Behavior (MDFCB) ratings.

    Time frame: These will be evaluated at Baseline, 6 months, and 12 months (end of study).

  3. Cost-effectiveness

    A prospective cost-effectiveness and cost-utility analysis will be performed comparing the experimental and control arms.

    Time frame: Baseline to End of Study (12 months)

  4. Participant engagement

    For the Intervention arm only, this is measured by the number of successful interactions between the Remote Patient Monitoring (RPM) team and participant.

    Time frame: Baseline to End of Study (12 months)

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 36 months is above that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 18, 2023
StartActual
Apr 22, 2026
Primary completionEst.
May 1, 2029
CompletionEst.
May 1, 2029
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05950659
Responsible party
Sponsor
First posted
Jul 18, 2023
Start date
Apr 22, 2026
Primary completion
May 1, 2029 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Jul 14, 2026

Study contacts

Emily Bray
Contact
emily.bray@orpyx.com
+1 (855) 996-7799
Caitlin Hicks, MD
principal investigator · John's Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion